多模态超声技术联合粪便钙卫蛋白评估炎症性肠病的临床研究

Multimodal Ultrasound Technology Combined with Fecal Calprotectin Assessment in Clinical Studies of Inflammatory Bowel Disease

目的:研究多模态超声技术联合粪便钙卫蛋白水平评估炎症性肠病的临床意义。方法:回顾性分析2022年1月~2023年10月在扬州大学附属医院接收诊疗的95例炎症性肠病患者的临床资料。根据简化克罗恩病活动指数将患者分为缓解期和活动期,并分别比较缓解期和活动期患者常规二维超声、彩色多普勒和超声造影的检查数据以及住院患者的粪便钙卫蛋白水平。结果:缓解期和活动期患者肠壁厚度、血流分级、超声造影定量参数(PI、WoAUC、FT和mTT)之间存在统计学差异(p < 0.05)。结论:多模态超声联合粪便钙卫蛋白水平评估炎症性肠病炎症反应的严重程度具有一定临床指导意义。

Purpose: This study aimed to assess the clinical significance of multimodal ultrasound combined with fecal calprotectin levels in the evaluation of inflammatory bowel disease (IBD). Methods: We conducted a retrospective analysis of clinical data from 95 patients with IBD treated at Yangzhou University Affiliated Hospital between January 2022 and October 2023. Patients were categorized into remission and active phases based on the Simplified Crohn’s Disease Activity Index. We compared routine two-dimensional ultrasound, color Doppler, and contrast-enhanced ultrasound findings between patients in remission and active phases, as well as fecal calprotectin levels in hospitalized patients. Results: Significant statistical differences (p < 0.05) were observed in intestinal wall thickness, blood flow grading, and quantitative parameters from contrast-enhanced ultrasound (Peak Kinetic Index, Washout Area under the Curve, Final Time, and mean Transit Time) between patients in remission and active phases. Conclusion: Multimodal ultrasound combined with fecal calprotectin levels provides valuable clinical insights into assessing the severity of inflammatory bowel disease inflammation.